Oral vaccine of recombinant Lactococcus lactis expressing the VP1 protein of duck hepatitis A virus type 3 induces mucosal and systemic immune responses. Issue 31 (18th July 2019)
- Record Type:
- Journal Article
- Title:
- Oral vaccine of recombinant Lactococcus lactis expressing the VP1 protein of duck hepatitis A virus type 3 induces mucosal and systemic immune responses. Issue 31 (18th July 2019)
- Main Title:
- Oral vaccine of recombinant Lactococcus lactis expressing the VP1 protein of duck hepatitis A virus type 3 induces mucosal and systemic immune responses
- Authors:
- Song, Shasha
Li, Pengfei
Zhang, Ruihua
Chen, Junhao
Lan, Jingjing
Lin, Shaoli
Guo, Guanjie
Xie, Zhijing
Jiang, Shijin - Abstract:
- Highlights: A L. lactis expressing VP1 protein of DHAV-3 was successfully constructed. Effective cellular and humoral immunity was induced in the immunized mice. Effective cellular and humoral immunity was induced in the immunized ducklings. The immunized ducklings were effectively protected from natural infection of DHAV-3. Abstract: Duck hepatitis A virus (DHAV) is the major pathogen of duck viral hepatitis, which has caused great economic losses to duck breeding industry. As an effective delivery tool for protein antigens, Lactococcus lactis ( L. lactis ) has been successfully used to stimulate mucosal and systemic immune response. In this study, a recombinant L. lactis named NZ3900-VP1 was constructed, which could express VP1 protein of DHAV type 3 (DHAV-3) by using a nisin-controlled expression (NICE) system. The animal experiment in both mice and ducklings were performed to detect the immune response and protection effect of oral vaccination by the recombinant L. lactis . The results showed that oral vaccination with L. lactis NZ3900-VP1 significantly induced specific anti-VP1 IgG antibodies and mucosal secretory immunoglobulin A (sIgA) of DHAV-3 in mice and ducklings, and cytokines including interleukin-2 (IL-2), interferon gamma (IFN-γ), interleukin-10 (IL-10) and interleukin-4 (IL-4). Notably, the ducklings vaccinated with L. lactis NZ3900-VP1 were effectively protected when facing natural infestation of DHAV-3, which indicated that the recombinant L. lactis couldHighlights: A L. lactis expressing VP1 protein of DHAV-3 was successfully constructed. Effective cellular and humoral immunity was induced in the immunized mice. Effective cellular and humoral immunity was induced in the immunized ducklings. The immunized ducklings were effectively protected from natural infection of DHAV-3. Abstract: Duck hepatitis A virus (DHAV) is the major pathogen of duck viral hepatitis, which has caused great economic losses to duck breeding industry. As an effective delivery tool for protein antigens, Lactococcus lactis ( L. lactis ) has been successfully used to stimulate mucosal and systemic immune response. In this study, a recombinant L. lactis named NZ3900-VP1 was constructed, which could express VP1 protein of DHAV type 3 (DHAV-3) by using a nisin-controlled expression (NICE) system. The animal experiment in both mice and ducklings were performed to detect the immune response and protection effect of oral vaccination by the recombinant L. lactis . The results showed that oral vaccination with L. lactis NZ3900-VP1 significantly induced specific anti-VP1 IgG antibodies and mucosal secretory immunoglobulin A (sIgA) of DHAV-3 in mice and ducklings, and cytokines including interleukin-2 (IL-2), interferon gamma (IFN-γ), interleukin-10 (IL-10) and interleukin-4 (IL-4). Notably, the ducklings vaccinated with L. lactis NZ3900-VP1 were effectively protected when facing natural infestation of DHAV-3, which indicated that the recombinant L. lactis could serve as an effective vaccine to prevent DHAV-3 infection in ducklings. … (more)
- Is Part Of:
- Vaccine. Volume 37:Issue 31(2019)
- Journal:
- Vaccine
- Issue:
- Volume 37:Issue 31(2019)
- Issue Display:
- Volume 37, Issue 31 (2019)
- Year:
- 2019
- Volume:
- 37
- Issue:
- 31
- Issue Sort Value:
- 2019-0037-0031-0000
- Page Start:
- 4364
- Page End:
- 4369
- Publication Date:
- 2019-07-18
- Subjects:
- Duck hepatitis A virus type 3 (DHAV-3) -- VP1 -- Lactococcus lactis (L. lactis) -- Oral vaccination
DHAV-3 duck hepatitis A virus type 3 -- NICE nisin-controlled expression -- L. lactis Lactococcus lactis -- IgG immunoglobulin G -- sIgA secretory immunoglobulin A -- IL-2 interleukin-2 -- IFN-γ interferon gamma -- IL-4 interleukin-4 -- IL-10 interleukin-10
Vaccines -- Periodicals
615.372 - Journal URLs:
- http://www.sciencedirect.com/science/journal/0264410X ↗
http://www.clinicalkey.com/dura/browse/journalIssue/0264410X ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/0264410X ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.vaccine.2019.06.026 ↗
- Languages:
- English
- ISSNs:
- 0264-410X
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 9138.628000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 10932.xml